On March, 27 WallStreet expected Netshoes (NYSE:Cayman Limited)’s earnings release, Zacks reports. Analysts forecast $0.05 EPS. That’s $0.39 up or 114.71 % from 2018’s earnings of $-0.34. If EPS of $0.05 is published the profit of NETS could be $1.55 million giving it 11.45 P/E. Last quarter $-1.10 EPS was reported. Analysts forecasts -104.55 % EPS growth this quarter. Cayman Limited is hitting $2.29 during the last trading session, after decreased 4.58%.Currently Netshoes is after 0.00% change in last March 6, 2018. Cayman Limited has also 9,544 shares volume. Cayman Limited underperformed the S&P500 by 4.37%.
Netshoes Limited, through its subsidiaries, operates as a sports and lifestyle online retailer in Latin America.The firm is worth $71.12 million. It offers various products, including athletic shoes, jerseys, apparels, accessories, and sporting equipment of international, local, and private brands, as well as fashion.Currently it has negative earnings. The firm operates through its ecommerce Websites, such as www.netshoes.com and www.zattini.com.
For more Netshoes (NYSE:Cayman Limited) news posted briefly go to: Benzinga.com, Businesswire.com, Globenewswire.com, Benzinga.com or Globenewswire.com. The titles are as follows: “54 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” posted on February 19, 2019, “WX INVESTOR ALERT: Rosen Law Firm Reminds WuXi PharmaTech (Cayman) Inc. Investors of Important Deadline in Securities Class Action Lawsuit – WX – Business Wire” on March 03, 2019, “ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against WuXi PharmaTech (Cayman) Inc. – WX – GlobeNewswire” with a publish date: February 26, 2019, “75 Biggest Movers From Yesterday – Benzinga” and the last “Pomerantz Law Firm Announces the Filing of a Class Action against WuXi PharmaTech (Cayman) Inc. and Certain Officers – WX – GlobeNewswire” with publication date: February 22, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.